Clinical Activity and Safety Profile of TGR-1202, a Novel Once Daily PI3K-Delta Inhibitor, Demonstrates Clinical Activity with a Favorable Safety Profile, Lacking Hepatotoxicity in Patients with CLL and B-Cell Lymphoma.

Drug Category : Array
Conference Category : Array
Lead Author : O'Connor, et al.
Published Date : 20/06/2015
Download Link : https://www.tgtherapeutics.com/wp-content/uploads/2019/03/O'ConnorTGR202Single%20AgentEHA&Lugano2015(1).pdf
Download Text : Download
Popup Confirmation? :
site-sidebar-layout : default
ast-site-content-layout : default
site-content-style : default
site-sidebar-style : default
theme-transparent-header-meta : default
stick-header-meta : default
astra-migrate-meta-layouts : set
Scroll to Top